Microbiome Consortium Design Patents: Who Leads, Where the Gaps Are 2026
Microbiome Consortium Design Patents: Concentration at the Top, a Long Tail Behind It
Five companies hold 40.2% of the field. 88 of 219 records in scope sit with the top five ranked assignees, with a further tail of 68 companies filing far fewer each. Filings rose from 3 in 2017 to a peak of 38 in 2020, then settled into a plateau: 2021 and 2024 both recorded 24 filings, a 0% change over that three-year span. Treat the final one to two years as undercounted given publication lag.
- 1VEDANTA BIOSCIENCES INC27
- 2UNIV OF MARYLAND17
- 3THE TRUSTEES OF THE UNIV OF PENNSYLVANIA17
- 4FINCH THERAPEUTICS HLDG LLC14
- 5GUSTO GLOBAL LLC13
See the full microbiome consortium design analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in microbiome consortium design?
The ranking covers 73 companies, and it is genuinely top-heavy: the leading assignee alone holds 27 records, more than double the fifth-place count of 13. Together the top five hold 88 of 219 records in scope, or 40.2% of the field, and the top ten extend that to 62.1%. The remaining 63 companies in the ranking split the rest thinly, which points to a field where a handful of therapeutics developers and university programs set the claim boundaries that everyone else files around.
Is patent filing in microbiome consortium design still growing?
Filing peaked at 38 in 2020 and has since leveled off, with 2021 and 2024 both recording 24 filings — a flat 0% change over that span. This is a plateau rather than a decline. It is also worth noting that publication typically lags filing by about 18 months, so the 2025 and 2026 figures in any dataset are still incomplete and should not be read as a downturn.
What does US11810650B2 actually cover?
US11810650B2, granted to Gusto Global, LLC in November 2023, claims methods for rationally designing stable microbial consortia by identifying and complementing functional gaps in a host’s microbiome relative to healthy subjects. The core inventive concept is building consortia with deliberate metabolic interdependencies to improve engraftment, stability and performance once administered. Anyone drafting claims around function-complementation logic for consortium design should review its specific claim scope closely, since it sits squarely in the metabolic-complementarity approach this dataset tracks.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Microbiome Consortium Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.